Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma Fund
Direct Plan where a fund has one, Growth option · Data as on 30-10-2026
Motilal Oswal BSE Healthcare ETF is an ETF fund and Nippon India Pharma Fund is a Sectoral fund. In the 3 years to 30-10-2026, Motilal Oswal BSE Healthcare ETF returned 22.7% a year and Nippon India Pharma Fund (Direct) returned 18.6% a year. Motilal Oswal BSE Healthcare ETF charges 0.36% a year and Nippon India Pharma Fund 0.99%. Their portfolios overlap 59.5%: they hold 34 of the same securities.
Motilal Oswal BSE Healthcare ETF
ETF
- 3 year return
- 22.7%
- Expense ratio
- 0.36%
- NAV
- ₹50.91
Nippon India Pharma Fund
Sectoral
- 3 year return
- 18.6%
- Expense ratio
- 0.99%
- NAV
- ₹625.46
Which is better, Motilal Oswal BSE Healthcare ETF or Nippon India Pharma? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Motilal Oswal BSE Healthcare ETF returned more over 3 years: 22.7% a year against 18.6%.
- Motilal Oswal BSE Healthcare ETF returned more over 1 year: 12.2% against 9.1%.
- Motilal Oswal BSE Healthcare ETF costs less: 0.36% a year against 0.99%.
- Nippon India Pharma swung less over 3 years: a standard deviation of 13.0% a year against 14.1%.
- Nippon India Pharma fell less in its worst fall since 04-08-2022: −14.7% against −16.1%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹44 Cr.
- Their portfolios overlap 59.5%: 34 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Motilal Oswal BSE Healthcare ETF | Nippon India Pharma Fund |
|---|---|---|
| Fund house | Motilal Oswal Mutual Fund | Nippon India Mutual Fund |
| Category | ETF | Sectoral |
| AUM | ₹44 Cr (30-09-2026) | ₹9,166 Cr (30-09-2026) |
| NAV | ₹50.91 | ₹625.46 (Direct) |
| Expense ratio (Direct) | Not available | 0.99% |
| Expense ratio (Regular) | Not available | 1.85% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 29-07-2022 | 05-06-2004 |
| Minimum investment | ₹500 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Swapnil Mayekar, Rakesh Shetty | Sailesh Raj Bhan |
| Exit load | Nil | Exit load of 1% if redeemed within 1 month. |
Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | +0.22% | −1.05% | +12.72% | +12.16% | +22.69% | -- | -- |
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
Category average: the average of the 20 Sectoral funds, same plan type.
Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma: Year-wise Returns
| Year | Motilal Oswal BSE Healthcare ETFMotilal Oswal BSE Healthcare ETF | Nippon India PharmaNippon India Pharma | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +14.90% | +9.76% | +15.08% |
| 2025 | −2.93% | −2.46% | −2.72% |
| 2024 | +43.80% | +35.26% | +44.30% |
| 2023 | +37.59% | +40.36% | +37.97% |
| 2022 | -- | −9.06% | −11.50% |
| 2021 | -- | +25.12% | +21.54% |
Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 3-year holding period, 305 of them, one for each trading day from 04-08-2025 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Motilal Oswal BSE Healthcare ETF
Nippon India Pharma Fund (Direct)
BSE Healthcare TRI
to
Sept 2025Nov 2022
to
Nov 2025Feb 2023
to
Feb 2026Apr 2023
to
Apr 2026Jul 2023
to
Jul 2026Sept 2023
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 72.5 | 25.9 | 24.1% | 24.2% | 19.5% | 28.4% | 0% |
| Nippon India Pharma | 0.0 | 0.0 | 0.0 | 0.0 | 21.4 | 72.0 | 6.6 | 22.2% | 22.6% | 15.9% | 26.7% | 0% |
| BSE Healthcare TRI | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 63.3 | 36.1 | 24.5% | 24.6% | 19.8% | 28.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 04-08-2022. Past returns do not promise future returns.
Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 04-08-2022 to 30-10-2026: 51 instalments, ₹5,10,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETFMotilal Oswal BSE Healthcare ETF | ₹5,10,000 | ₹7,62,270 | ₹2,52,270 | 19.2% |
| Nippon India PharmaNippon India Pharma Fund (Direct) | ₹5,10,000 | ₹7,13,501 | ₹2,03,501 | 15.9% |
Motilal Oswal BSE Healthcare ETFMotilal Oswal BSE Healthcare ETF
Nippon India PharmaNippon India Pharma Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Motilal Oswal BSE Healthcare ETF | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +12.16% | +9.05% |
| Standard deviation | 13.58% | 12.27% |
| Sharpe ratio | 0.51 | 0.31 |
| Sortino ratio | 0.75 | 0.45 |
| Maximum drawdown | −10.0% (23-10-2026) | −9.6% (23-10-2026) |
| Beta | 1.00 | 0.87 |
| Alpha | −0.20% | −2.40% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Motilal Oswal BSE Healthcare ETF | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +22.69% | +18.56% |
| Standard deviation | 14.08% | 12.96% |
| Sharpe ratio | 1.18 | 0.97 |
| Sortino ratio | 1.68 | 1.39 |
| Maximum drawdown | −16.1% (28-02-2025) | −14.7% (28-02-2025) |
| Beta | 1.00 | 0.88 |
| Alpha | −0.28% | −2.50% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Motilal Oswal BSE Healthcare ETF | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +20.31% | +17.18% |
| Standard deviation | 13.22% | 15.19% |
| Sharpe ratio | 1.07 | 0.73 |
| Sortino ratio | 1.54 | 1.06 |
| Maximum drawdown | −16.1% (28-02-2025) | −24.0% (29-05-2017) |
| Beta | 1.00 | 0.85 |
| Alpha | −0.29% | +3.72% |
From daily NAVs, 04-08-2022 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Motilal Oswal BSE Healthcare ETF
Nippon India Pharma Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | −16.1% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
| Nippon India Pharma Fund (Direct) | −14.7% | 02-01-2025 | 28-02-2025 | 24-07-2025 | 5 months | −4.3% |
| BSE Healthcare TRI | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
From daily values since 04-08-2022, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Motilal Oswal BSE Healthcare ETF
Nippon India Pharma Fund (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Motilal Oswal BSE Healthcare ETF
Nippon India Pharma Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | 99% | 100% | 0.06% |
| Nippon India Pharma Fund (Direct) | 91% | 91% | 3.56% |
From month-end values since 04-08-2022. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma: Portfolio Overlap
From each fund's latest monthly portfolio: Motilal Oswal BSE Healthcare ETF, September 2026; Nippon India Pharma Fund, September 2026
Holdings in common
- Overlap
- 59.5%
- Held by both
- 34
- Only in Motilal Oswal BSE Healthcare ETF
- 103
- Only in Nippon India Pharma
- 2
| Security | % of Motilal Oswal BSE Healthcare ETF | % of Nippon India Pharma |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 12.33% | 11.71% |
| Divi's Laboratories Limited | 7.42% | 7.10% |
| Apollo Hospitals Enterprise Limited | 5.21% | 4.89% |
| Cipla Limited | 4.79% | 6.01% |
| Dr Reddys Laboratories Limited | 4.73% | 5.45% |
| Lupin Limited | 3.11% | 6.17% |
| Max Healthcare Institute Limited | 4.32% | 2.70% |
| Alkem Laboratories Limited | 1.89% | 1.82% |
| Mankind Pharma Limited | 1.75% | 4.38% |
| IPCA Laboratories Limited | 1.69% | 2.87% |
| Aurobindo Pharma Limited | 2.89% | 1.65% |
| Gland Pharma Limited | 1.44% | 2.53% |
| Sai Life Sciences Limited | 1.30% | 3.92% |
| Fortis Healthcare Limited | 2.51% | 1.13% |
| Ajanta Pharma Limited | 1.02% | 3.61% |
| Biocon Limited | 1.63% | 1.01% |
| Dr. Lal Path Labs Limited | 0.96% | 2.17% |
| Abbott India Limited | 0.87% | 2.32% |
| Piramal Pharma Limited | 0.81% | 2.24% |
| Narayana Hrudayalaya Limited | 0.78% | 1.61% |
| GlaxoSmithKline Pharmaceuticals Limited | 0.71% | 3.11% |
| Anthem Biosciences Limited | 0.58% | 1.19% |
| Emcure Pharmaceuticals Ltd | 0.51% | 1.36% |
| Vijaya Diagnostic Centre Limited | 0.45% | 2.62% |
| Syngene International Limited | 0.43% | 1.40% |
| Pfizer Limited | 0.37% | 1.35% |
| AstraZeneca Pharma India Limited | 0.24% | 0.42% |
| Thyrocare Technologies Limited | 0.21% | 2.24% |
| Akums Drugs and Pharmaceuticals Limited | 0.18% | 1.21% |
| Concord Biotech Limited | 0.29% | 0.17% |
| Sanofi India Limited | 0.17% | 1.00% |
| Sanofi Consumer Healthcare India Limited | 0.16% | 0.89% |
| Indoco Remedies Limited | 0.06% | 0.48% |
| Suraksha Diagnostic Limited | 0.04% | 1.51% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 59.5% means 59.5% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Motilal Oswal BSE Healthcare ETF
| Security | % of fund |
|---|---|
| Laurus Labs Limited | 4.84% |
| Torrent Pharmaceuticals Limited | 3.55% |
| Glenmark Pharmaceuticals Limited | 2.17% |
| Zydus Lifesciences Limited | 1.82% |
| Krishna Institute Of Medical Sciences Limited | 1.24% |
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| MedPlus Health Services Limited | 2.53% |
| Molbio Diagnostics Limited | 0.54% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Motilal Oswal BSE Healthcare ETF | Nippon India Pharma |
|---|---|---|
| Equity | 99.9% | 97.3% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.1% | 2.7% |
Market cap of stocks
| Market cap | Motilal Oswal BSE Healthcare ETF | Nippon India Pharma |
|---|---|---|
| Large Cap | 33.3% | 29.7% |
| Mid Cap | 38.5% | 39.0% |
| Small Cap | 27.8% | 28.0% |
| Not on AMFI's list | 0.3% | 0.5% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Motilal Oswal BSE Healthcare ETF | Nippon India Pharma |
|---|---|---|
| Pharmaceuticals & Biotechnology | 78.0% | 74.0% |
| Healthcare Services | 21.4% | 20.3% |
| Retailing | 0.0% | 2.5% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Motilal Oswal BSE Healthcare ETF | Nippon India Pharma Fund |
|---|---|---|
| Total expense ratio (Direct) | Not available | 0.99% |
| Base expense ratio (Direct) | 0.00% | 0.79% |
| Total expense ratio (Regular) | Not available | 1.85% |
| Base expense ratio (Regular) | 0.21% | 1.52% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Motilal Oswal BSE Healthcare ETF vs Nippon India Pharma Fund: Frequently Asked Questions
What is the difference between Motilal Oswal BSE Healthcare ETF and Nippon India Pharma Fund?
Motilal Oswal BSE Healthcare ETF is an ETF fund, Nippon India Pharma Fund is a Sectoral fund, run by Motilal Oswal Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 59.5%. Motilal Oswal BSE Healthcare ETF charges 0.36% a year and Nippon India Pharma Fund 0.99%.
Which has given higher returns, Motilal Oswal BSE Healthcare ETF or Nippon India Pharma Fund?
Over 1 year: Motilal Oswal BSE Healthcare ETF +12.16%, Nippon India Pharma Fund +9.05%. Over 3 years: Motilal Oswal BSE Healthcare ETF +22.69% a year, Nippon India Pharma Fund +18.56% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Motilal Oswal BSE Healthcare ETF or Nippon India Pharma Fund?
Motilal Oswal BSE Healthcare ETF charges less: 0.36% a year against 0.99%. These are the total expense ratios reported to AMFI.
How much do Motilal Oswal BSE Healthcare ETF and Nippon India Pharma Fund overlap?
59.5%. They hold 34 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, APOLLOHOSP. From each fund's latest monthly portfolio.
Which is riskier, Motilal Oswal BSE Healthcare ETF or Nippon India Pharma Fund?
On SEBI's riskometer, Motilal Oswal BSE Healthcare ETF is rated Very High and Nippon India Pharma Fund Very High. Over 3 years, the standard deviation of daily returns was 14.08% and 12.96% a year.
Which is better for SIP, Motilal Oswal BSE Healthcare ETF or Nippon India Pharma Fund?
Over the last 3 years, a monthly SIP of ₹10,000 from 03-10-2023 to 30-10-2026 grew to ₹4,63,433 in Motilal Oswal BSE Healthcare ETF (XIRR 14.8% a year) and ₹4,36,963 in Nippon India Pharma Fund (XIRR 10.8% a year). Both received 37 instalments. Past returns do not promise future returns.
Can I invest in both Motilal Oswal BSE Healthcare ETF and Nippon India Pharma Fund?
Yes. 59.5% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Motilal Oswal BSE Healthcare ETF and Nippon India Pharma Fund?
Motilal Oswal BSE Healthcare ETF: Swapnil Mayekar, Rakesh Shetty. Nippon India Pharma Fund: Sailesh Raj Bhan.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.